[Correspondence] Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer

In their Article, Brose and colleagues1 report that vemurafenib has antitumour activity in patients with progressive BRAFV600E-positive papillary thyroid cancer refractory to radioactive iodine who have previously been treated with a multikinase inhibitor or not. This non-randomised, open-label, phase 2 trial gives a strong rationale for targeted BRAF inhibition in patients with thyroid cancer, confirming previous reports. However, we believe that crucial information is not reported that might help guide clinical practice.

http://ift.tt/2eO6nW8